Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 16/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778018 | 1.00 | TBXA2R (0.51) | TBXA2RPTGDR2S1PR1PTGER1PTGER4 | |
| SCHEMBL5775915 | 0.93 | TBXA2R (0.45) | TBXA2RPTGDR2S1PR1PTGER1PTGER4 | |
| SCHEMBL5774986 | 0.84 | TBXA2R (0.51) | TBXA2RPTGDR2S1PR1 | |
| SCHEMBL5775625 | 0.84 | S1PR1 (0.47) | TBXA2RS1PR1 | |
| SCHEMBL5776896 | 0.83 | TBXA2R (0.52) | TBXA2RPTGDR2PTGER3PTGER2PTGIR | |
| SCHEMBL5774455 | 0.83 | TBXA2R (0.40) | TBXA2RPTGDR2S1PR1PTGDR | |
| SCHEMBL5777326 | 0.83 | TBXA2R (0.44) | TBXA2RPTGDR2S1PR1 | |
| SCHEMBL5835717 | 0.82 | TBXA2R (0.45) | TBXA2RPTGDR2PTGDRPDE2A | |
| SCHEMBL5775723 | 0.82 | S1PR1 (0.47) | TBXA2RPTGDR2S1PR1 | |
| SCHEMBL5771752 | 0.82 | TBXA2R (0.52) | TBXA2RPTGDR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | TBXA2R 22/4885PTGDR2 2/4885S1PR1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.